Skip to Content

More Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma Can Participate in Clinical Studies

This study, presented at EHA 2024 by Jelena Jelicic, shows that selecting patients for clinical trials based on the National Comprehensive Cancer Network IPI (NCCN-IPI) leads to more patients qualifying to participate in clinical trials. However, the study also shows that a smaller population of patients with excellent prognoses is excluded from participation.

Jelena Jelicic

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top